1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics
  4. >>In Vitro Diagnostics

Researchers Recommend Wider Distribution Of First EUA-Cleared COVID-19 Test Using Smartphone Technology

 
• By Malcolm Spicer

BD has EUA for Veritor At-Home COVID-19 rapid antigen test using smartphone vision technology to interpret and digitally display results. Researchers at biotech firms and medical schools measure advantages of at-home use of rapid antigen tests over quantitative real-time polymerase chain reaction tests.

Professional doctor in a smartphone giving a consultation online and checking a radiography, telemedicine and healthcare concept, blank copy space

US emergency use authorizations for at-home COVID-19 tests reached smartphone technology for the first time while researchers say increasing OTC access to rapid antigen tests is key to accelerating detections of infections.

Becton, Dickinson and Co. on 25 August announced the Food and Drug Administration issued an EUA for the BD Veritor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from In Vitro Diagnostics

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Astrin Biosciences To Launch First Blood-Based Test For Early Breast Cancer Detection, Dense Breasts

 
• By Marion Webb

Astrin Biosciences will debut Certitude, a proteomics-based blood test for women with dense breasts, aiming to detect early breast cancer with MRI-like accuracy and outperform current supplemental imaging.

HistoSonics Closed $250M Funding To Expand, But IPO ‘Not Immediate Priority,’ Says CEO

 
• By Marion Webb

The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.

Successful Diagnostics Alter Clinical Pathways, Says NHS Foundation Trust Leader

 
• By Natasha Barrow

Evidence-based testing in real clinical settings and diagnostics tailored to community needs are crucial adoption success factors for new IVDs, Michael Wright, joint medical director at Newcastle Hospitals NHS Foundation Trust, told Medtech Insight at a regional UK meeting.

More from Diagnostics

Astrin Biosciences To Launch First Blood-Based Test For Early Breast Cancer Detection, Dense Breasts

 
• By Marion Webb

Astrin Biosciences will debut Certitude, a proteomics-based blood test for women with dense breasts, aiming to detect early breast cancer with MRI-like accuracy and outperform current supplemental imaging.

Is 30-Day Response Window In FDA Warning Letter A Mistake Or Shift In Policy?

 
• By Brian Bossetta

Two recent warning letters from the US FDA provide the companies with 30 business days to respond instead of the usual 15. Though not a regulatory requirement, the 15-day time frame has become the standard.

Could Oura Take A Bite Out Of Apple? Company Seeks FDA Clearance For Blood Pressure Feature

 
• By Brian Bossetta

Wearables innovator Oura has launched a profile study aimed at helping the company secure FDA clearance for a blood pressure feature for its smart ring. Study participants will answer questions while wearing the ring, which the company plans to use to support the feature’s efficacy.